Ardelyx Inc.

236 articles about Ardelyx Inc.

• Ardelyx Inc. To Report Third Quarter 2014 Financial Results On November 6, 2014

  10/30/2014

• Ardelyx Inc.'s Tenapanor Selected For Oral And Poster Presentations At The American Society of Nephrology's Kidney Week 2014

  10/23/2014

• Ardelyx Inc. Looks Good After Tenanpanor Results: Citi Analysts

  10/1/2014

• Ardelyx Inc. Irritable Bowel Syndrome Drug Succeeds In Phase 2b Trial

  10/1/2014

• Ardelyx Inc. Chief Scientific Officer, Dominique Charmot, Announces Retirement From The Company At Year-End

  9/5/2014

• Ardelyx Inc. To Present At The Wedbush 2014 Life Sciences Management Access Conference

  8/5/2014

• Ardelyx Inc. Announces Full Exercise Of Underwriters' Option To Purchase Additional Shares

  6/25/2014

• Fremont Biotech Ardelyx Inc. Prices IPO At $14 Per Share

  6/19/2014

• Bay Area's Ardelyx Inc. Lowers IPO Target Slightly, Now Hopes To Raise Up To $62 Million

  6/11/2014

• Fremont-Based Ardelyx Inc. Files For $69 Million IPO

  5/22/2014

• Ardelyx Inc. Receives $25 Million Milestone From AstraZeneca PLC For Commencement Of Phase 2b Clinical Trial Of Tenapanor

  5/15/2014

• Bay Area's Ardelyx Inc. Nabs Kidney Disease Pact Worth $198 Million With Pharma Giant Sanofi (France)

  2/24/2014

• Ardelyx Inc. Receives $15 Million Milestone As Part of Ongoing Tenapanor Collaboration With AstraZeneca PLC

  1/13/2014

• AstraZeneca PLC Boosts Pipeline With $272 Million Ardelyx Inc. Drug Deal

  10/9/2012

• Ardelyx Inc. Closes $30 Million Series B Financing

  8/31/2011

• Ardelyx Inc. Appoints Mark Kaufmann to Chief Business Officer

  8/31/2011